Malinda Prewitt, MD
Infectious Disease · Tupelo, MSNPI 1710941315
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Merck at 32.3% of the total. Reporting peaked in 2022 at $268 and has fallen 62.8% since, to $99 in 2025.
Across 40 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$288
- La Jolla Pharmaceutical Company$260
- AbbVie$167
- Tetraphase Pharmaceuticals, Inc.$84
- Viiv Healthcare Company$49
- Cumberland Pharmaceuticals, Inc.$42
What the payments were for
- Food & beverage$890100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 13 | $288 |
| La Jolla Pharmaceutical Company | 11 | $260 |
| AbbVie(2 entities) | 10 | $167 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $84 |
| Viiv Healthcare Company | 2 | $49 |
| Cumberland Pharmaceuticals, Inc. | 1 | $42 |
How this compares
$890 in reported general payments places this provider in the 65th percentile of 36 infectious disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 37 | $44,203 |
| ErtapenemErtapenem Sodium | 20 | $7,652 |
| Cefepime Hcl | 26 | $5,798 |
| Vancomycin Hcl | 23 | $3,037 |
| Sodium Chloride0.9 % Sodium Chloride | 109 | $1,267 |
| Cefazolin Sodium | 14 | $1,133 |
| CeftriaxoneCeftriaxone Sodium | 15 | $373 |
| Levofloxacin | 11 | $59 |
| Diphenhydramine Hcl | 12 | $40 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Tupelo
- Max TaylorTupelo$537
- Jesse PenicoGulfport$49K
- Jo DealJackson$9K
- Svenja AlbrechtJackson$5K
- Olatunji OluwatadeVicksburg$3K
- Satwinder SinghGreenville$2K
- Thompson LiddellHattiesburg$2K
- Rathel NolanJackson$2K
- Jason MossHattiesburg$2K
- Richard FlowersJackson$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.